Clinical Trial Protocol
Iranian Registry of Clinical Trials

07 Nov 2026

Comparesion between treatment with Bosweilia serrata against placebo to change the progression of cognitive disorders in Multiple sclerosis patients

Protocol summary

Summary

Multiple sclerosis is a demyelinating disease of central nervous system. Cognitive impairment is one of important disorder in these patients that have prevalence about 34-65%. Boswellia serrata is a substance that has been used for the augmentation of memory and learning skills in the past. There are plenty of studies focusing on the anti-inflammatory effects of Boswellia serrata. In addition of anti-inflammatory effects, neuroprotective properties have been reported. Since MS is an inflammatory disease and cognitive impairment is one of the influential elements on the life of MS patients, the effect of Boswellia serrata on the cognitive impairment of MS patients is investigated in the present work using BICAMS test.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2013070813911N1**
Registration date: **2013-08-22, 1392/05/31**
Registration timing: **retrospective**

Last update:
Update count: **0**

Registration date

2013-08-22, 1392/05/31

Registrant information

Name

Behnaz Sedighi

Name of organization / entity

Kerman University of Medical Sciences, Shafa hospital

Country

Iran (Islamic Republic of)

Phone

+98 34 1211 5817

Email address

b-sedighi@kmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Neurology Research Center,Kerman University of Medical Sciensec, Kerman, Iran

Expected recruitment start date

2013-02-19, 1391/12/01

Expected recruitment end date

2013-06-22, 1392/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparesion between treatment with Bosweilia serrata against placebo to change the progression of cognitive disorders in Multiple sclerosis patients

Public title

Effect of Bosweilia serrata in prevention of cognitive impairment progression in multiple sclerosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criterion: definite multiple sclerosis. Exclusion criteria: taking new drugs; hypersensitivity to Bosweilia serrata and drug side effect.

Age

No age limit

Gender

Both

Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: **74**
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Neurology Research Center,Kerman University of Medical Sciensec, Kerman, Iran
Street address
shafa hospital,kerman
City
kerman
Postal code
Approval date
2013-02-13, 1391/11/25
Ethics committee reference number
K/91/379

Health conditions studied

1

Description of health condition studied
Multiple sclerosis
ICD-10 code
G35
ICD-10 code description
Multiple sclerosis

Primary outcomes

1

Description
Cognitive impairment
Timepoint
Befor intervention and 2month later
Method of measurement
BICAMS TEST

Secondary outcomes

empty

Intervention groups

1

Description
cap Bosweilia serrata 300mg BD. 2 months for intervention group
Category
Treatment - Drugs

2

Description
Cap placebo 300mg BD ,2 months for control group
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
infirmery multiple sclerosis, Shafa hospital
Full name of responsible person
Street address
Shafa hospital
City
Kerman

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Kerman University of Medical Sciensec
Full name of responsible person
Dr. Malekpur
Street address
jomhuri bool, Kerman university of medical sciense
City
Kerman
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kerman University of Medical Sciensec
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty

Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Shafa hospital, Kerman University of Medical Sciences
Full name of responsible person
Behnaz Sedighi
Position
Associate professor
Other areas of specialty/work
Street address
Shafa hospita
City
Kerman
Postal code
Phone
+98 34 1211 5780
Fax
Email
Behnaz.sedighi@gmail.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shafa hospital, Kerman University of Medical Sciences
Full name of responsible person
Bhnaz Sedighi
Position
Associate professor
Other areas of specialty/work
Street address
Shafa hospital
City
Kerman
Postal code
Phone
+98 34 1211 5780
Fax
Email
Behnaz.sedighi@gmail.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Shafa hospital, Kerman University of Medical Sciences
Full name of responsible person
Behnaz Sedighi
Position
Associate professor
Other areas of specialty/work
Street address
Shafa hospital
City
Kerman
Postal code
Phone
+98 34 1211 5780
Fax
Email
behnaz.sedighi@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty